Clover Health (CLOV) Jumps 19.4% on "Buy" Reco

We recently published 10 Stocks Beating Wall Street’s Bets. Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the best performers on Friday.

Clover Health surged by 19.37 percent on Friday to close at $3.82 apiece as investors took heart from a “buy” recommendation from an investment firm.

In a market note, Zacks Research upgraded Clover Health Investments, Corp. (NASDAQ:CLOV) to “buy,” following an upward trend in earnings estimates—one of the most powerful forces impacting stock prices.”

“For the fiscal year ending December 2025, [Clover Health Investments, Corp. (NASDAQ:CLOV)] is expected to earn $0.10 per share, which is unchanged compared with the year-ago reported number. Analysts have been steadily raising their estimates for Clover Health Investments. Over the past three months, the Zacks Consensus Estimate for the company has increased 25 percent,” the note said.

Based on its historical reporting dates, Clover Health Investments, Corp. (NASDAQ:CLOV) is expected to release the results of its third quarter financial and operating highlights on November 6, 2025.

While we acknowledge the potential of CLOV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.